How is AI changing drug discovery today and where will it go from here?

Listen as Adrian Dawkes talks to Kurt Herpel, CEO and Klaus Kratochwill, CSO of Delta 4, an Austrian /Swiss based AI tech company. Hear how their AI journey began more than 20 years ago and how the company developed into a key player in AI drug discovery. Hear how their clients are already benefiting from AI. You will hear their insights into;

• Where AI is benefiting drug discovery processes today?
• How will it be used in the future, will we get better drugs faster?
• Can it replace the need for human involvement?
• Will AI impact on the discovery and use of new biomarkers?

To find out what the diagnostics deal making landscape looks like for you, you can request an initial complimentary consultation with the experts in this podcast via email: enquiries@pharmaventures.com

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, .Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry